Good find ER. Kelly and Recknor are shown as "Abst

Good find ER. Kelly and Recknor are shown as "Abstract authors".

I saw this under "Presentations" for 6/25/22 at the link below:

Efficacy and safety of leronlimab in patients with nonalcoholic steatohepatitis: topline results of NASH01 clinical trial
Mazen Noureddin, United States

https://events-program.easl.eu/ProgramSearch/...ogin=False

Leronlimab is one of six presentations listed on Dr. Noureddin's page at link below. I have not seen how that correlates with Recknor/Kelly. Perhaps he is running a session where they present?? He is on CYDY's Scientific Advisory Board.

In any event, he has quite the pedigree. Here is some info about him.

Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center (currently ranked #2 in GI and GI surgery per US News). Dr. Noureddin did his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He then joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recruited to Cedars-Sinai Medical Center in 2015 to establish its new fatty liver program. Dr. Noureddin is internationally known for his research in the area of NAFLD/NASH and NASH related cirrhosis. He conducted more than 40 investigational clinical studies of novel treatments for NASH. In addition, he is an expert in non-invasive testing and biomarkers of the field, especially serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. He has published in all these areas and has been invited to consensus panels on this topic by multiple societies including the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver Diseases (EASL). He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the vice chair of the AASLD NASH special interest group (will be chairing the group in 2023) and serves on the editorial board for major GI journals including “Gastroenterology”, “Hepatology” and “Clinical Gastroenterology and Hepatology (CGH)”. He is one of the new Associate Editors of “Clinical Gastroenterology and Hepatology (CGH)” starting 2022. He is funded by the National Cancer Institute and has served as a reviewer on NIH study section. He has published in many journals including: The Lancet, Science Trinational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, Clinical Gastroenterology and Hepatology and others.

https://events-program.easl.eu/ProgramSearch/...vate=False